QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho’s common stock over the next two years.
Morgan Stanley Maintains Equal-Weight on AppLovin, Raises Price Target to $16
Morgan Stanley analyst Matthew Cost maintains AppLovin (NASDAQ:APP) with a Equal-Weight and raises the price target from $15 to $16.
